Rallybio (RLYB) Expected to Announce Earnings on Thursday

Rallybio (NASDAQ:RLYB) is expected to post its Q4 2025 results before the market opens on Thursday, March 12th. Analysts expect the company to announce earnings of ($1.04) per share for the quarter. Investors are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Tuesday, March 10, 2026 at 12:30 PM ET.

Rallybio Stock Down 1.8%

NASDAQ RLYB opened at $10.51 on Thursday. Rallybio has a 52 week low of $1.76 and a 52 week high of $11.49. The company has a 50 day moving average price of $5.65 and a 200 day moving average price of $5.20. The firm has a market cap of $55.49 million, a PE ratio of -4.11 and a beta of -1.13.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Rallybio in a research report on Monday, December 29th. Four investment analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Reduce” and a consensus target price of $40.00.

Hedge Funds Weigh In On Rallybio

Several hedge funds and other institutional investors have recently modified their holdings of RLYB. XTX Topco Ltd lifted its holdings in Rallybio by 64.6% in the fourth quarter. XTX Topco Ltd now owns 97,313 shares of the company’s stock valued at $67,000 after acquiring an additional 38,205 shares during the last quarter. Susquehanna International Group LLP raised its position in Rallybio by 485.9% in the third quarter. Susquehanna International Group LLP now owns 136,294 shares of the company’s stock valued at $68,000 after purchasing an additional 113,031 shares during the period. Geode Capital Management LLC lifted its stake in shares of Rallybio by 1.2% in the 4th quarter. Geode Capital Management LLC now owns 248,005 shares of the company’s stock valued at $170,000 after purchasing an additional 2,996 shares during the last quarter. Citadel Advisors LLC grew its holdings in shares of Rallybio by 576.1% during the 3rd quarter. Citadel Advisors LLC now owns 438,705 shares of the company’s stock worth $219,000 after purchasing an additional 373,821 shares during the period. Finally, Renaissance Technologies LLC increased its position in shares of Rallybio by 16.9% during the 4th quarter. Renaissance Technologies LLC now owns 835,692 shares of the company’s stock worth $573,000 after purchasing an additional 120,892 shares during the last quarter. 90.34% of the stock is owned by hedge funds and other institutional investors.

About Rallybio

Rallybio Therapeutics, Inc (NASDAQ: RLYB) is a clinical‐stage biotechnology company focused on developing and commercializing therapies for people living with rare genetic diseases. The company’s scientific approach leverages diverse modalities—including monoclonal antibodies, small molecules and enzyme replacement—to address high‐unmet‐need conditions in areas such as immunodeficiency, metabolic disorders and dermatologic diseases. Rallybio’s pipeline is designed to advance through registrational clinical trials with the goal of delivering first‐in‐class or best‐in‐class therapies to patients who currently have limited or no approved treatment options.

Among Rallybio’s lead programs is RBX‐100, an investigational therapy for congenital athymia, a rare pediatric immunodeficiency.